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Context: Hypophosphatasia (HPP) is a syndrome marked by low serum alkaline phosphatase (AlkP) activity as well as musculoskeletal and/or dental disease. While the majority of subjects with HPP carry a
pathogenic variant in the ALPL gene or its regulatory regions, individual pathogenic variants are often not
tightly correlated with clinical symptomatology. We sought to better understand the genotype/phenotype correlation in HPP by examining the clinical and biochemical data of 37 subjects with 2 rare variants in ALPL.
Methods: Through BioVU, a DNA biobank that pairs individuals’ genetic information with their
de-identified medical records, we identified subjects with 2 rare variants with distinct reported clinical phenotypes (p.D294A and p.T273M). We then performed a manual review of these subjects’
de-identified medical records along with computational modeling of protein structure to construct a
genetic, biochemical and clinical phenotype for each subject and variant.
Results: Twenty subjects with the p.D294A variant and 17 with the p.T273M variant had sufficient
data for analysis. Among subjects in our cohort with the p.D294A variant, 6 (30.0%) had both clinical
bone disease and serum AlkP activity below 40 IU/L while 4 subjects (23.5%) with the p.T273M variant met the same criteria despite the distinct clinical phenotypes of these variants.
Conclusions: Given the loose genotype/phenotype correlation in HPP seen in our cohort, clinical
context is crucial for the interpretation of genetic test results to guide clinical care in this population.
Otherwise, over- or under-diagnosis may occur, resulting in misidentification of those who may benefit
from additional screening and perhaps pharmacologic intervention.
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Methods
Subject identification
The cohort studied for this case series was taken from BioVU, Vanderbilt’s de-identified
DNA biobank that pairs DNA isolated from leftover clinical blood samples from across the
medical center with a de-identified and randomly date-shifted image of the electronic health
record as previously described [22]. In 2012-2013, approximately 40 000 subjects in BioVU
were genotyped using the Illumina Infinium HumanExome BeadChip (http://genome.sph.
umich.edu/wiki/Exome_Chip_Design), which includes >240 000 mostly exonic markers,
as well as single nucleotide polymorphisms (SNPs) from the genome-wide association
study (GWAS) catalog [23]. Genotyping was performed at the Vanderbilt Technologies for
Advanced Genomics (VANTAGE) Core, and genomic data were processed by the Vanderbilt
Technologies for Advanced Genomics Analysis and Research Design (VANGARD) Core.
Genotyping quality was evaluated using SNP call rates and concordance rates with HapMap
controls; SNPs with <99.8% call rate or <98% concordance were excluded [24]. Further
details about GWAS coverage and quality control protocols have previously been discussed
in detail [25].
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Hypophosphatasia (HPP) is a disorder of reduced serum activity of the tissue nonspecific
alkaline phosphatase (TNSALP) protein, a product of the ALPL gene [1-6]. Subjects with
ALPL variants have a widely variable clinical phenotype, likely due to variable expressivity and incomplete penetrance, from neonatal seizures and hypomineralization to isolated dental or joint disease in adults [3, 7-11]. Those with mild phenotypes may progress
into adulthood with subclinical disease and present only as older adults after years of subclinical disease [1, 9, 12]. If these subjects come to clinical attention, it is often due to
mild, nonspecific findings or incidental findings on otherwise routine lab evaluation which
prompts further evaluation and ultimately a diagnosis of HPP [13, 14]. This highly variable clinical phenotype leads to significant diagnostic challenges, particularly in those with
minor disease manifestations or a phenotype that may have multiple potential etiologies
[8, 15-17]. While there are no formal criteria for diagnosis of HPP, factors often considered
supportive of a diagnosis include an alkaline phosphatase (AlkP) value below the normal
range for age/sex and clinical features such as bone and/or dental disease consistent with
the diagnosis [1-3, 16]. However, as more becomes known about the genetic and biochemical
underpinnings of the disease, genetic testing is often offered to subjects to help clarify their
diagnosis [1, 3, 9, 16, 18].
While significant effort has been expended to catalog and identify pathogenic variants
in the ALPL gene, the rarity of the diagnosis has complicated these efforts [16, 19].
Furthermore, with more than 400 described variants, knowledge about the effect of a particular variant is usually based upon clinical experience with an extremely small cohort
of subjects [9, 20]. The absence of larger cohorts and the lack of clear genotype-phenotype
correlations makes diagnosis difficult and can lead to both over- and under-diagnosis
[17]. Subjects with genetic testing positive for a pathogenic variant may undergo further testing and monitoring and ultimately never develop symptomatic disease [13].
Conversely, other subjects may have genetic testing results demonstrating no variant
or a variant of undetermined significance; this can inappropriately be interpreted by
providers to be inconsistent with HPP, resulting in exclusion of subjects who may otherwise require additional testing and treatment [14, 21]. To better understand the relationship between genotype and phenotype, we identified subjects with TNSALP mutations
from a general population database and reviewed their medical records for evidence of an
HPP phenotype. Through this unbiased approach, we are able to better understand the
phenotypic diversity of individuals with 2 variants to aid better understand phenotypic
diversity in this disease.
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Ethics statement

Case identification
We identified 13 ALPL SNPs which passed quality control as described above. The Illumina
chip included 13 variants in the ALPL gene on the HumanExome BeadChip. Each variant was initially reviewed for this study. From the 13 identified variants, 2 were selected
for further study—ALPL: rs121918002 (c.881A>C, p.D294A) and rs148405563 (c.818A>T,
p.T273M) as they had sufficient subject numbers (having at least 15 subjects within the
BioVU database), were sufficiently rare (minor allele frequency [MAF] <0.002), and had adequate lab data (at least 2 AlkP values during the study time period) [27]. The total number
of subjects in the cohort was 37; variant data are summarized in Table 1.
Manual chart review
We then performed a manual record review to better define the clinical phenotype of subjects
with these variants. The de-identified chart was accessed in the BioVU interface, which
allows review of the entire medical record of each subject. A search function was used to identify key phrases within documents to flag them for further review. For bone disease, chart
documents were flagged for review if they included the following terms: fracture, broken,
broken bone, broke, compression, lumbar, long bone, humeral, radial, clavicular, sternal,
tibial, fibular, femoral, spinal, cervical, thoracic, metaphyseal, spondylolisthesis, spondylosis, scoliosis, osteonecrosis, CPPD, pseudogout, gout, pyrophosphate, osteoporosis, osteopenia, osteomalacia, rickets, DEXA, bone density, osteogenesis, short stature, stone, calculus.
Charts were similarly flagged for review of dental disease if they included the following
terms: dental, teeth, tooth, dental fractures, extractions, tooth loss, broken tooth, broken
teeth, caries, periodontal, tooth extraction, crown, implant, tooth abscess, ONJ, TMJ, osteonecrosis of the jaw, cracking, chipping. A blinded manual abstraction of the medical records
was performed by 2 independent reviewers for the 37 total subjects with identified ALPL
variants. Records were manually abstracted to document clinical and laboratory findings
consistent with the known skeletal and dental phenotype of HPP. On average, electronic
health record (EHR) data from 2000 to 2012 were reviewed, which also includes problem
lists, lab results, imaging reports, and narrative reports from the EHR. AlkP assays were
performed by a single lab as a part of routine clinical care. The assay used during this time
period was a photometric assay done at nonphysiologic pH and with an artificial substrate.
This assay has the following reference ranges for age and sex: 0 to 14 days, 90-273 U/L;
15 days to <1 year, 134-518 U/L; 1 year to <10 years, 156-369 U/L; 10 to <13 years, 141-460
U/L; 13 years to <15 years, 62-280 U/L (female [F]) and 127-517 U/L (male [M]); 15 years to
Table 1.

SNP

ALPL Variants Identified Among Subjects Included as Cases

rsID

exm28158 rs121918002
exm28148 rs148405563

Previously Reported
Phenotype [20]
Infantile [3]
Asymptomatic, low
BMD [14]

Molecular
consequence

Functional
Consequence

c.881A > C p.D294A 35% normal [37]
c.818C > T p.T273M
Unknown

Carrier
Count MAF [27]
20
17

0.00002
0.00118

Abbreviations: BMD, bone mineral density; MAF, minor allele frequency—the frequency of the second most common
allele in a given population to differentiate between common and rare variants; rsID, accession number assigned to
refer to specific SNPs; SNP, single nucleotide polymorphism.

Downloaded from https://academic.oup.com/jes/article/4/8/bvaa084/5864159 by Washington University School of Medicine Library (M2) user on 08 June 2022

This project was determined to be nonhuman subject research by the Vanderbilt Institutional
Review Board [VUMC IRB# 120277], since there are no personal health identifiers in the
dataset. In accordance with the ethical framework previously described for BioVU studies
[26], all investigators must have IRB determination prior to accessing the resource and also
must sign a standard data use agreement [22, 26].
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<17 years, F 54-128 U/L, M 89-365 U/L; 17 years to <19 years, F 48-95 U/L, M 59-164 U/L.
Descriptive statistics were calculated manually as presented in Table 2.
Computational modeling

Results
Among the 40 000 patients who had been evaluated at our facility for any reason and for
whom SNP data was available, 2 variants were identified for further study. The first variant, p.D294A, has previously been studied in vitro and has 8.9% of native protein function
and shows negligible dominant negative effect [36]. In vivo, this variant has been found to
be disease-causing with a broad range of ages of onset and disease severity [5, 37, 38]. The
MAF of 0.00002 demonstrates that this is a rare variant in the population but was detected
within our sample in 20 subjects of approximately 40 000 screened [32]. The second variant,
p.T273M, has been reported in the literature as causing low AlkP and low bone mineral density [14, 39]. Recent data show this variant to have near normal in vitro enzymatic activity
Table 2. Aggregate Demographic, Alkaline Phosphatase, and Skeletal Phenotype Data Skeletal
Observed Within the Study Populations Defined by Their Genetic Variants
Demographics
Number of subjects with variant
Age (SD)
Percent Female
Alkaline Phosphatase
Mean (SD)*
Subjects with at least one AlkP under 50
Subjects with at least one AlkP under 40
Bone Disease
Scoliosis
Low bone mineral density
Long bone fractures
Spine fractures
Dental disease
Disease Phenotype
Both AlkP <40 and disease phenotype

p.D294A

p.T273M

20
60.2 (28.65)
35.0%

17
71.8 (19.05)
35.3%

59.6 (42.47)
17 (85%)
16 (80%)

50.65 (11.95)
15 (88.2%)
8 (47.1%)

2 (10.0%)
4 (20.0%)
2 (10.0%)
2 (10.0%)
1 (5.0%)

4 (23.5%)
7 (41.2%)
6 (35.3%)
2 (11.8%)
3 (17.6%)

6 (30.0%)

4 (23.5%)

Phenotypic data are the result of a manual chart review of subjects with each of the noted SNPs. No subject had
a clinical diagnosis of hypophosphatasia.
Dental disease included dental fractures, extractions, or other tooth loss. Long bone fractures included humeral,
radial, clavicular, sternal, tibial, fibular, or femoral fractures. Spinal fractures included cervical, thoracic, lumbar,
or sacral fracture.
*reference range 40–150 (IU/L).
Abbreviation: AlkP, alkaline phosphatase.
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A model of dimeric TNSALP was generated using RosettaCM to combine elements from
2 template crystal structures [28]. The model was based on 4kjg.pdb (rat intestinal alkaline phosphatase) and 1zef.pdb (human placenta alkaline phosphatase) [29, 30]. In order
to compare the location of each variant to the spatial distributions of known benign versus
disease-associated variants, the PathProx algorithm was used to map known ExAC and
ClinVar missense variants to the structure and calculate a relative proximity score [31, 32].
Thermodynamic destabilization by the variants was predicted using Rosetta’s ddG_monomer application, which calculates energy scores for the structure before and after mutation, allowing repacking of sidechains without backbone movement [33]. Because the model
was not a high-resolution x-ray crystal structure, the low-resolution protocol was used, corresponding to row 3 of Table 1 from Kellogg et al [33]. Molecular graphics were generated
using UCSF Chimera (supported by NIH P41 RR-01081) as distributed by SBGRID [34, 35].
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Figure 1. Location of variants of interest, metal ions, and other known pathogenic variants
within the dimeric alkaline phosphatase, tissue-nonspecific isozyme (TNSALP) homodimer.
Structural model of dimeric TNSALP, showing the location of the p.D294A and p.T273M variants (cyan) in the context of the pathogenic variants collected from ClinVar (red) and bound
zinc and magnesium ions (blue). The p.D294A substitution has a higher PathProx score (0.44
vs 0.10) compared to the p.T273M variant, indicating greater spatial colocalization with the
pathogenic variants than with the neutral distribution from ExAC.
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without a dominant negative effect [36]. No data regarding the in vivo enzymatic activity
for this variant was identified in our review of the literature. While still rare, this variant
is slightly more common in the general population, with an MAF of 0.00118, and it was present in 17 subjects within our sample [27].
Computational modeling of the TNSALP protein was performed to provide additional
insight into the impact of the variants in this study. The p.D294A variant is highlighted
in Fig. 1 within the dimeric TNSALP enzyme. This mutation, D294A, was analyzed using
PathProx, an algorithm which compares the proximity to the 3D distribution of known pathogenic variants from the ClinVar database versus proximity to the putative neutral variants
from the ExAC database. The PathProx score of 0.44 indicates strong colocalization with
pathogenic variants. This variant also produced a positive value of 2.0 in Rosetta’s deltadelta-G calculation, predicting thermodynamic destabilization of the structure as a result
of the mutation. In contrast, the p.T273M variant scored only 0.10 by PathProx, indicating
weaker colocalization with known disease-associated variants. It also produced a small negative delta-delta-G score of −1.51, suggesting a minor overstabilizing effect, if any.
Detailed chart review of this cohort of subjects demonstrated that regardless of their
variant, the majority of subjects had at least one HPP associated finding—a low AlkP
activity or clinical history associated with HPP—and a smaller, but significant number
had both associated findings (Table 2). Despite this, none of the subjects had a clinical
diagnosis of HPP. While those with the p.T273M variant were slightly older than those
in the p.D294A cohort (71.8 years vs 60.2 years, respectively), the cohorts were similar
in number and sex composition. As would be predicted from previous in vitro work noted
above, subjects in the p.D294A cohort were more likely to have at least one abnormally
low AlkP value (80% vs 47.1%). Interestingly, while these low values were more common
in the p.D294A cohort, the mean serum AlkP was lower in the p.T273M cohort compared
with those with the p.D294A variant (53.92 vs. 70.67). In terms of clinical phenotype, bone
and dental disease (scoliosis, fractures, low bone mineral density, and dental disease)
identified during chart review were each more common among patients with the p.T273M
variant. The rate of long bone fractures was 10.0% in the p.D294A cohort and 35.3% in
the p.T273M group. The rate of scoliosis was 10.0% in the p.D294A cohort and 23.5% in
the p.T273M group. Finally, 30.0% of the p.D294A cohort had both a low AlkP activity and
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Discussion
Current knowledge about genotype/phenotype correlations in HPP are limited by the condition being an uncommon diagnosis caused by a multitude of ALPL variants. Additional
complexity occurs as ALPL variants can exhibit a dominant‐negative effect as a result of
interactions between mutated and wild‐type monomers, and it has been suggested that
clinical presentation of HPP may be affected by strength of the dominant‐negative effect
[36]. We evaluated the phenotypes of subjects with 2 distinct variants in the ALPL gene
who did not have a clinical diagnosis of HPP, and thus, our cohort is likely to include a
broad representation of the clinical manifestations of HPP, not driven by presumptive diagnosis. Despite using multiple methods to attempt to predict a phenotype consistent with
disease, no single predictor, including in vitro assays, in silico modeling, and in vivo enzyme
activity, consistently correlated with disease in our cohort. With respect to the p.D294A variant, our in silico modeling gives a clear hypothesis for the observed decreased functional
activity of this enzyme due to the replacement of the negatively charged aspartate residue
by a neutral alanine in the active site of the enzyme. This is also reflected in the in vivo
results from the chart review of subjects, as they have low-normal average levels of serum
AlkP levels and frequently have serum AlkP levels below the lower limit of normal. Despite
the correlation between genotype and enzymatic phenotype, only 30% of subjects with this
variant have both a low serum AlkP and a musculoskeletal manifestation consistent with
the clinical disease. In contrast, the molecular modeling in the p.T273M variant places this
away from the enzymatic active site and metal or collagen binding domains, making a clear
hypothesis about the biologic consequence of this residue change more difficult to construct.
Furthermore, recent evidence suggests that this variant does not result in a significant

Figure 2. Subject data for those with the p.D294A variant.

Downloaded from https://academic.oup.com/jes/article/4/8/bvaa084/5864159 by Washington University School of Medicine Library (M2) user on 08 June 2022

clinical findings associated with disease while these were observed together in 23.5% of
the p.T273M group.
On an individual level, there was no observed correlation between average serum AlkP
and clinical manifestations of disease (Figs. 2 and 3). In subjects with the p.D294A variant,
all subjects except for subjects 7, 8, 19, and 20 had at least one recorded AlkP below the
lower limit of normal, but only subjects 1 through 8 had a finding in their clinical history
consistent with disease. This left subjects 1 through 6 with both a low AlkP level and a clinical manifestation associated with HPP. All subjects within this genotype cohort except for
subjects 19 and 20 had a least one biochemical or clinical history marker associated with
HPP. Among those with the p.T273M variant, subjects 21 to 24 and 32 to 36 had at least one
low AlkP value while subjects 21 to 31 each had at least one clinical feature consistent with
disease. Subjects 21 to 24 had both a low AlkP and at least one disease-related manifestation associated with HPP. Within this genotype cohort, all subjects except for subject 37 had
either a biochemical or clinical history consistent with disease. Interestingly, while many
subjects in the p.T273M cohort had multiple bone or dental findings, only subjects 1 and 2
in the p.D294A had multiple co-occurring markers on clinical history.
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reduction in enzyme activity alone or when co-expressed with the wild-type enzyme [36].
However, patients in this cohort had a serum AlkP less than the lower limit of normal (40
IU/L) and a similar proportion had an orthopedic manifestation. The lack of correlation between enzymatic activity and phenotypic manifestations in this cohort suggests that better
understanding the protein structure changes induced by these variants outside of their enzymatic function may be needed to more fully explain the pathogenic mechanisms in this
disease process.
Of note, while previous observations have suggested that HPP is more prevalent in
women [13, 21], our sample contains equal numbers of women and men who had both
clinical criteria associated with diagnosis. While not definitive due to a lack of complete
clinical information and the small sample size of our cohort, this suggests that reports of
higher rates of HPP diagnosis among women may be a product of our current diagnostic
assumptions and not a characteristic of the underlying disease.
Taken together, our data have several implications for clinical practice and future study.
In contrast to previous work with patients with pediatric onset HPP, our sample of mostly
adults who have less severe HPP-associated disease shows minimal, if any, concordance
between serum AlkP levels and clinical disease [15]. While one might expect that lower
serum alkaline phosphatase activities would predict more severe musculoskeletal disease,
this was not the case among our cohort. Indeed, among our cohort, even those with mean
AlkP within the normal range were noted to have symptoms consistent with disease, while,
on the other hand, several subjects with mean AlkP activities well below the lower limit of
normal had no skeletal manifestations discovered during chart review. This lack of concordance between in vitro activity and clinical disease suggests that other pathways may be able
to either exacerbate or diminish the effects of even small changes in TNSALP enzymatic
activity. Furthermore, while potentially an artifact of our relatively small sample size, the
observation that the mean AlkP activity among those with the p.T273M was lower than in
those with the p.D294A variant despite in vitro assays requires further study to better understand the molecular basis of this observation
Our data have several strengths. Because our cohort is drawn from all patients presenting
to our medical facility, and inclusion is solely based on genotype, we are better able to
capture the entire spectrum of disease manifestations and not only those with severe disease seen in subspecialty clinics. As a retrospective review of the entire medical records of
these subjects, we were able to retrospectively capture clinical data for decades, and review
radiology reports and subspecialty notes, ensuring dense medical history. Similarly, most
subjects also had AlkP values from multiple time points, ensuring an accurate reflection
of the AlkP trends over time. However, our study has multiple limitations. First, our genotype data are the result of GWAS screening, and while it includes multiple loci within
the TNSALP gene, it is by no means comprehensive, and without further sequencing we
cannot exclude the possibility that our patients may have additional undetected variants.
Additionally, as a retrospective study, our sample is vulnerable, particularly among the
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Figure 3. Subject data for those with the p.T273M variant.
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